Nguyen Huong Giang Trinh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nguyen Huong Giang Trinh has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Dinh Chau Nguyen
Department of Radiation Oncology and Radiosurgery, 108 Military Central Hospital, Hanoi 100000, Vietnam
2 shared publications - Dinh Thuy Mai
Faculty of Engineering Physics, Hanoi University of Science and Technology, Hanoi 100000, Vietnam
2 shared publications - Huu Quyet Nguyen
Institute for Nuclear Science and Technology, Hanoi 100000, Vietnam
2 shared publications - Khac Nam Vo
Nuclear Medicine Department, HCM Oncology Hospital, Ho Chi Minh City 700000, Vietnam
2 shared publications - Ngoc Ha Bui
Faculty of Engineering Physics, Hanoi University of Science and Technology, Hanoi 100000, Vietnam
2 shared publications - Ngoc Toan Tran
Institute for Nuclear Science and Technology, Hanoi 100000, Vietnam
2 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by MDPI AG in Journal of Imaging
- Vol. 12 (8) , 364
Benchmarking Deep Learning for NSCLC PET/CT Segmentation on a Histologically Confirmed Vietnamese Dataset: Validation and Generalization
Accurate segmentation of non-small cell lung cancer (NSCLC) on positron emission tomography/computed tomography (PET/CT) is an essential prerequisite for automated metabolic tumor volume (MTV) quantification and staging. Although deep learning models achieve high performance on large-scale datasets, their generalization across different clinical domains is limited by variations in imaging protocols and patient demographics. This study aims to evaluate several deep learning architectures and investigate a transfer learning strategy to mitigate domain shift. Three architectures, including ResNet-backbone 3D U-Net, nnU-Net v2, and Swin UNETR, were benchmarked from scratch and compared with a fine-tuned nnU-Net initialized with AutoPET II weights. Results on the internal dataset showed that the fine-tuned nnU-Net achieved a Dice similarity coefficient (DSC) of 83.4 ± 6.5%, a 95% Hausdorff distance (HD95) of 5.1 ± 3.6 mm, and a precision of 89.6 ± 8.2%. Compared to the nnU-Net v2, the fine-tuned nnU-Net improved the absolute DSC by 6.8% while reducing local training time by 37.5% by bypassing the initial feature-learning phase. The fine-tuned nnU-Net model also demonstrated a high correlation between the MTV and the ground truth (Pearson r = 0.96, p < 0.001), indicating its potential as a reliable automated approach for quantitative MTV extraction and NSCLC prognostic-related analysis.
- 8 August 2026
- Published by MDPI AG in Journal of Imaging
- Vol. 12 (8) , 364
Open AccessBenchmarking Deep Learning for NSCLC PET/CT Segmentation on a Histologically Confirmed Vietnamese Dataset: Validation and Generalization
Accurate segmentation of non-small cell lung cancer (NSCLC) on positron emission tomography/computed tomography (PET/CT) is an essential prerequisite for automated metabolic tumor volume (MTV) quantification and staging. Although deep learning models achieve high performance on large-scale datasets, their generalization across different clinical domains is limited by variations in imaging protocols and patient demographics. This study aims to evaluate several deep learning architectures and investigate a transfer learning strategy to mitigate domain shift. Three architectures, including ResNet-backbone 3D U-Net, nnU-Net v2, and Swin UNETR, were benchmarked from scratch and compared with a fine-tuned nnU-Net initialized with AutoPET II weights. Results on the internal dataset showed that the fine-tuned nnU-Net achieved a Dice similarity coefficient (DSC) of 83.4 ± 6.5%, a 95% Hausdorff distance (HD95) of 5.1 ± 3.6 mm, and a precision of 89.6 ± 8.2%. Compared to the nnU-Net v2, the fine-tuned nnU-Net improved the absolute DSC by 6.8% while reducing local training time by 37.5% by bypassing the initial feature-learning phase. The fine-tuned nnU-Net model also demonstrated a high correlation between the MTV and the ground truth (Pearson r = 0.96, p < 0.001), indicating its potential as a reliable automated approach for quantitative MTV extraction and NSCLC prognostic-related analysis.
- Open Access
- 3 July 2026
- Published by MDPI AG in Preprints.org
Benchmarking Deep Learning for NSCLC PET/CT Segmentation on a Histologically Confirmed Vietnamese Dataset: Validation and Generalization
Accurate segmentation of non-small cell lung cancer (NSCLC) on positron emission tomography/computed tomography (PET/CT) is a critical foundation for automated metabolic tumor volume (MTV) quantification and staging. Although deep learning models achieve high performance on large-scale datasets, their generalization across different clinical domains remains challenged by variations in imaging protocols and patient demographics. This study aims to evaluate several deep learning architectures and investigate a transfer learning strategy to mitigate domain shift on a dataset of 400 PET/CT scans from Vietnamese NSCLC patient cohort. Three architectures, including 3D U-Net, nnU-Net v2, and Swin UNETR, were benchmarked from scratch and compared with a fine-tuned nnU-Net initialized with AutoPET II weights. Results on the internal dataset showed that the fine-tuned nnU-Net achieved a Dice similarity coefficient (DSC) of 83.4 ± 6.5%, a 95% Hausdorff distance (HD95) of 5.1 ± 3.6 mm, and precision of 89.6 ± 8.2%. Compared to the nnU-Net v2, the fine-tuned nnU-Net improved the absolute DSC by 6.8% while reducing the training time by 37.5%. The fine-tuned nnU-Net model also demonstrated a good correlation between the MTV and the ground truth (Pearson r = 0.96, p < 0.001), indicating its potential as a reliable automated approach for quantitative MTV extraction and NSCLC prognostic related analysis.
- 3 July 2026
- Published by MDPI AG in Preprints.org
Open AccessBenchmarking Deep Learning for NSCLC PET/CT Segmentation on a Histologically Confirmed Vietnamese Dataset: Validation and Generalization
Accurate segmentation of non-small cell lung cancer (NSCLC) on positron emission tomography/computed tomography (PET/CT) is a critical foundation for automated metabolic tumor volume (MTV) quantification and staging. Although deep learning models achieve high performance on large-scale datasets, their generalization across different clinical domains remains challenged by variations in imaging protocols and patient demographics. This study aims to evaluate several deep learning architectures and investigate a transfer learning strategy to mitigate domain shift on a dataset of 400 PET/CT scans from Vietnamese NSCLC patient cohort. Three architectures, including 3D U-Net, nnU-Net v2, and Swin UNETR, were benchmarked from scratch and compared with a fine-tuned nnU-Net initialized with AutoPET II weights. Results on the internal dataset showed that the fine-tuned nnU-Net achieved a Dice similarity coefficient (DSC) of 83.4 ± 6.5%, a 95% Hausdorff distance (HD95) of 5.1 ± 3.6 mm, and precision of 89.6 ± 8.2%. Compared to the nnU-Net v2, the fine-tuned nnU-Net improved the absolute DSC by 6.8% while reducing the training time by 37.5%. The fine-tuned nnU-Net model also demonstrated a good correlation between the MTV and the ground truth (Pearson r = 0.96, p < 0.001), indicating its potential as a reliable automated approach for quantitative MTV extraction and NSCLC prognostic related analysis.
- Open Access
- 10 June 2024
- Published by Vietnam Medical Journal, Vietnam Medical Association in Tạp chí Y học Việt Nam
- Vol. 539 (2)
ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ CỦA PHÁC ĐỒ BEVACIZUMAB – mFOLFOX6 TRONG ĐIỀU TRỊ BƯỚC 1 BỆNH NHÂN UNG THƯ ĐẠI TRỰC TRÀNG GIAI ĐOẠN IV
Mục tiêu: Đánh giá kết quả và tác dụng không mong muốn của phác đồ Bevacizumab – mFOLFOX6 trong điều trị bước 1 bệnh nhân ung thư đại trực tràng (UTĐTT) giai đoạn IV. Đối tượng và phương pháp nghiên cứu: Hồi cứu kết hợp tiến cứu, theo dõi dọc trên 41 bệnh nhân ung thư đại trực tràng giai đoạn IV theo AJCC 8th được điều trị bước 1 bằng phác đồ Bevacizumab – mFOLFOX6 tại bệnh viện Quân y 103 và bệnh viện Trung ương Quân đội 108 từ tháng 5/2019 đến tháng 12/2023. Kết quả: Trung vị thời gian sống thêm không bệnh tiến triển là 11 tháng. Tác dụng không mong muốn thường ở mức độ 1-2. Kết luận: Phác đồ Bevacizumab – mFOLFOX6 trong điều trị ung thư đại trực tràng giai đoạn di căn có hiệu quả điều trị cao và độc tính có thể kiểm soát được
- 10 June 2024
- Published by Vietnam Medical Journal, Vietnam Medical Association in Tạp chí Y học Việt Nam
- Vol. 539 (2)
Open AccessĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ CỦA PHÁC ĐỒ BEVACIZUMAB – mFOLFOX6 TRONG ĐIỀU TRỊ BƯỚC 1 BỆNH NHÂN UNG THƯ ĐẠI TRỰC TRÀNG GIAI ĐOẠN IV
Mục tiêu: Đánh giá kết quả và tác dụng không mong muốn của phác đồ Bevacizumab – mFOLFOX6 trong điều trị bước 1 bệnh nhân ung thư đại trực tràng (UTĐTT) giai đoạn IV. Đối tượng và phương pháp nghiên cứu: Hồi cứu kết hợp tiến cứu, theo dõi dọc trên 41 bệnh nhân ung thư đại trực tràng giai đoạn IV theo AJCC 8th được điều trị bước 1 bằng phác đồ Bevacizumab – mFOLFOX6 tại bệnh viện Quân y 103 và bệnh viện Trung ương Quân đội 108 từ tháng 5/2019 đến tháng 12/2023. Kết quả: Trung vị thời gian sống thêm không bệnh tiến triển là 11 tháng. Tác dụng không mong muốn thường ở mức độ 1-2. Kết luận: Phác đồ Bevacizumab – mFOLFOX6 trong điều trị ung thư đại trực tràng giai đoạn di căn có hiệu quả điều trị cao và độc tính có thể kiểm soát được